Stockscreener 앱 받기
1.805
0.28%
-0.005
시간 외 거래:
1.83
0.025
+1.39%
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Cabaletta Bio stock hits 52-week low at $1.75 amid sharp decline - Investing.com India
Cabaletta Bio to Present at TD Cowen 45th Annual Health Care Conference - MSN
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference - TradingView
Can Cabaletta Bio's Conference Appearance Signal New Autoimmune Treatment Progress? - StockTitan
Is Now The Time To Buy Cabaletta Bio Inc (NASDAQ: CABA) Stock? - Stocks Register
Cabaletta Bio Reveals Promising Clinical Data for Autoimmune Therapy - MSN
HC Wainwright Reiterates Buy Rating for Cabaletta Bio (NASDAQ:CABA) - MarketBeat
Cabaletta Bio Inc (CABA) Stock: Navigating Drops and Gains - The InvestChronicle
Cabaletta Bio (NASDAQ:CABA) Given “Buy” Rating at HC Wainwright - Defense World
Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) PT at $22.71 - MarketBeat
Shopify Stock Forecast: Can SHOP Hit $175 in 2025? - The Globe and Mail
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Earnings To Watch: Herbalife (HLF) Reports Q4 Results Tomorrow - The Globe and Mail
UPDATECabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings - Yahoo Finance
What To Expect From Fiverr’s (FVRR) Q4 Earnings - The Globe and Mail
Cabaletta Bio’s rese-cel shows efficacy in clinical studies - TipRanks
Cabaletta Bio Unveils Promising Clinical Data in RESET Trials - TipRanks
Cabaletta Bio Announces Updated Clinical Data With Rese-Cel At February Scientific Meetings - Marketscreener.com
Revolutionary Autoimmune Treatment Success: Patients Achieve Complete Remission, Stop All Medications - StockTitan
Kyndryl Soars on AI, Cybersecurity Growth—What’s Next? - The Globe and Mail
Tri Pointe Homes (TPH) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 - MSN
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences - MSN
SG Americas Securities LLC Purchases 8,161 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech Conference - MSN
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February - The Manila Times
Cabaletta Bio to Present Updated Clinical Data on Rese-cel at 2025 Scientific Conferences - Nasdaq
Cabaletta Bio Inc (CABA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Teradata Earnings: What To Look For From TDC - The Globe and Mail
Jennison Associates LLC Cuts Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Recent uptick might appease Cabaletta Bio, Inc. (NASDAQ:CABA) institutional owners after losing 89% over the past year - Simply Wall St
Company’s Banking Stock: Dissecting a -35.00% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Will Palantir Be the World's Most Valuable Software Company? - The Globe and Mail
Does Cabaletta Bio Inc (CABA) offer a good opportunity for investors? - SETE News
Cabaletta Bio Inc (CABA) Stock: A Value Analysis - The News Heater
BlackRock, Inc. Reduces Stake in Cabaletta Bio Inc: A Strategic Portfolio Adjustment - GuruFocus.com
Cabaletta Bio Inc (CABA) requires closer examination - US Post News
What's Going On With Microsoft Stock? - The Globe and Mail
Market Highlights: Cabaletta Bio Inc (CABA) Ends on a High Note at 2.39 - The Dwinnex
Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference - The Manila Times
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference - GlobeNewswire Inc.
0.22%
0.81%
자본화:
|
볼륨(24시간):